403(r)(6) of the Act requires dietary supplement manufacturers to have substantiation that structure/function, nutrient deficiency, and general well‐being claims on a dietary supplement product’s labeling are truthful and not misleading. To meet this statutory requirement, we recommend that manufacturers possess adequate substantiation for each reasonable interpretation of the claims. We intend to apply a standard that is consistent with the FTC standard of “competent and reliable scientific evidence” to substantiate a claim. We consider the following factors important to establish whether information would constitute “competent and reliable scientific evidence”:
Does each study or piece of evidence bear a relationship to the specific claim(s)?
What are the individual study’s or evidence’s strengths and weaknesses? Consider the type of study, the design of the study, analysis of the results, and peer review.
If multiple studies exist, do the studies that have the most reliable methodologies suggest a particular outcome?
If multiple studies exist, what do most studies suggest or find? Does the totality of the evidence agree with the claim(s)?
* * * * *
5.8 MEDICAL FOODS
A medical food is “a food formulated to be consumed or administered under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”65 Medical foods are exempt from disease statement limitations and from the NLEA health claims requirements as long as they identify the diseased population for whom they are designed.66 Medical foods are also exempt from the NLEA labeling requirements for nutrient content claims.67
However, medical food is a narrow and special category. Medical food claims must be based on therapeutic or chronic medical needs. For instance, foods for those with genetic metabolic disorders. A medical food must be intended for a patient who has a limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or who has other special medically determined nutrient requirements.
While some diseases benefit from the consumption of certain types of foods, if those foods are available as part of a healthy diet and the nutrients within those foods are able to be absorbed by the patient, then the foods would not be considered medical foods. Rather, medical foods are foods that are specially formulated and processed for a patient who requires use of the product as a major component of a disease or condition’s specific dietary management. For example, vitamin C to cure or prevent the scurvy is not a medical food because the disease can be cured or prevented with a healthy diet. On the other hand, a food that eliminates or significantly restricts phenylalanine for treatment of phenylketonuria could be considered a medical food.
5.9 THERAPEUTIC AND RELATED DISEASE CLAIMS
A subcategory of health claims is drug claims. A drug claim is a claim that states or implies that a product is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease.
A product with an unapproved drug claim may result in multiple violations of the FD&C Act. The most obvious potential violation is the prohibition on false or misleading claims, but this is the least of the concerns. FDA has far easier options than being drawn into a factual battle over the quality and the quantity of scientific research supporting a therapeutic claim. Specifically, FDA is more likely to bring actions for violation as follows:
Marketing an unapproved new drug.68
Misbranding a drug by failing to include adequate directions for use.69
FDA may bring both charges against a product with unapproved therapeutic claims. This is sometimes referred to as the FDA “double squeeze.”
5.9.1 Marketing an Unapproved New Drug
A product intended to diagnose, cure, mitigate, treat, or prevent a disease is a drug under the FD&C Act and must meet the regulatory requirements for drugs.70 The claims made on the product’s labeling are a primary means of establishing the intended use of a product, but FDA is not limited to the product’s packaging. Any evidence of the product’s intended use may be used by FDA to establish that a product is intended to diagnose, cure, mitigate, treat, or prevent a disease. Disease claims, consumer testimonials, citation to scientific or clinical research, and word of mouth can all provide evidence that a product is intended to diagnose, cure, mitigate, treat, or prevent disease.
Any product that is not generally recognized, among experts qualified by scientific training and expertise to evaluate the safety and effectiveness of drugs, as safe and effective for the intended use (GRASE) is considered a “new drug.”71 Marketing a new drug in the United States without an FDA‐approved new drug application (NDA) violates the FD&C Act.72
Regardless of the quantity and quality of science supporting a therapeutic claim, that claim violates the FD&C Act if the product and claim are not governed by an approved NDA. Truth of the claim is no defense. FDA generally gets considerable deference in this area because unapproved therapeutic claims not only create the potential for economic loss, but may also put consumers’ health at risk.73 When unapproved new drugs are promoted for diseases, FDA is reasonably concerned that consumers may forgo necessary medical diagnosis and treatment to the detriment of their health.
5.9.2 Misbranded Drug Violations Based on Inadequate Directions for Use
Under section 502(f)(1) of the FD&C Act, FDA requires drugs to have adequate directions for safe and effective use.74 Many medical conditions are not amenable to self‐diagnosis and treatment by individuals who are not medical practitioners. For example, cancer may require advanced technology using radiological imaging and blood analysis that require a trained medical practitioner for diagnosis and treatment. Therefore, FDA may determine that adequate directions for use cannot be written for some therapeutic claims on a product such that a layperson can use the drug safely for its intended purposes.
Notes
1 1 21 C.F.R. § 101.14(a)(1).
2 2 21 C.F.R. § 101.14(c).
3 3 FDA, Qualified Health Claims: Letter of Enforcement Discretion—Walnuts and Coronary Heart Disease (Mar. 9, 2004) (Docket No. 02P‐0292).
4 4 21 C.F.R. § 101.14(e).
5 5 A disease means damage to an organ, part, structure, or system of the body such that it does not function properly (e.g., cardiovascular